HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primary Prevention Of Heart Risk Factors Trumps Secondary Prevention – BMJ

This article was originally published in The Tan Sheet

Executive Summary

Primary prevention strategies to reduce the CHD risk factors of smoking, high cholesterol and hypertension "achieved a four-fold larger reduction in deaths" compared to secondary prevention over a twenty-year period in the UK, according to a British Medical Journal study

You may also be interested in...



MHRA Looks To Triptans, Anti-Hypertensives As Next Switch Categories

The UK's Medicines & Healthcare products Regulatory Agency expects to review an application to reclassify a triptan for migraine from Prescription Only Medicine (POM) to Pharmacy (P) status in the next year and a half

Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement

Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

RS126971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel